Stage 3c melanoma survival rate by age

. 2020 Aug 1;38(22):2543-2551.

Table of Contents Show

Prognosis of Patients With Stage III Melanoma According to American Joint Committee on Cancer Version 8: A Reassessment on the Basis of 3 Independent Stage III Melanoma Cohorts
Similar articles
References
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
What is the life expectancy with stage 3 melanoma?
What are the chances of surviving stage 3 melanoma?
Is Stage 3 melanoma considered advanced?
How serious is Stage 3C melanoma?

doi: 10.1200/JCO.19.03034. Epub 2020 Jun 12.

Ulrike Keim 1 , Stefan Suciu 2 , Teresa Amaral 1 , Thomas K Eigentler 1 , Anja Gesierich 3 , Axel Hauschild 4 , Lucie Heinzerling 5 , Felix Kiecker 6 , Dirk Schadendorf 7 , Rudolf Stadler 8 , Cord Sunderkötter 9 , Thomas Tüting 10 , Jochen Utikal 11 , Uwe Wollina 12 , Christos C Zouboulis 13 , Ulrich Keilholz 14 , Alessandro Testori 15 , Peter Martus 16 , Ulrike Leiter 1 , Alexander M M Eggermont 17 , German Central Malignant Melanoma Registry and the European Organisation for Research and Treatment of Cancer

Affiliations

PMID: 32530760
PMCID: PMC7392743
DOI: 10.1200/JCO.19.03034

Free PMC article

Prognosis of Patients With Stage III Melanoma According to American Joint Committee on Cancer Version 8: A Reassessment on the Basis of 3 Independent Stage III Melanoma Cohorts

Claus Garbe et al. J Clin Oncol. 2020.

Free PMC article

Abstract

Purpose: Three new therapies have been approved recently for the adjuvant treatment of stage III melanoma, substantially reducing the risk of tumor recurrences. This study evaluates 3 independent data sets to clarify the survival probabilities of patients with stage III melanoma.

Patients and methods: The Central Malignant Melanoma Registry (CMMR) evaluated 1,553 patients with a primary diagnosis of stage III melanoma from 2000 to 2012. Studies from the European Organisation for Research and Treatment of Cancer (EORTC), of 573 patients in the observation arm of the 18991 study and 445 patients in the placebo arm of the 18071 study, were evaluated as reference cohorts. The survival outcomes were compared with the published American Joint Committee on Cancer version 8 (AJCCv8) stage III survival data.

Results: For the CMMR stage III cohort versus the AJCCv8 cohort, the melanoma-specific survival (MSS) rates at 5 years were 67% versus 77%, and at 10 years were 56% versus 69%, respectively. For stage IIIA, the MSS rates at 5 years were 80% versus 93%, and at 10 years were 71% versus 88%; for stage IIIB, the MSS rates at 5 years were 75% versus 83%, and at 10 years were 61% versus 77%. The MSS rates of the EORTC studies either overlapped with or were lower than, the CMMR data.

Conclusion: The MSS rates in the CMMR and EORTC cohorts over the entire stage III are less favorable than those published in AJCCv8. This is particularly true for substages IIIA and IIIB.

Figures

FIG 1.

Kaplan-Meier curves for melanoma-specific survival (MSS) in the Central Malignant Melanoma Registry cohort. (A) In all stage III patients. (B) According to American Joint Committee on Cancer version 8 (AJCCv8) classification: stage IIIA, IIIB, IIIC, and IIID. HR, hazard ratio.

FIG 2.

Kaplan-Meier curves for melanoma-specific survival (MSS) in European Organisation for Research and Treatment of Cancer cohort 18991, observation group. (A) In all stage III patients. (B) According to American Joint Committee on Cancer version 8 (AJCCv8) classification: stage IIIA, IIIB, IIIC, and IIID. HR, hazard ratio.

FIG 3.

Kaplan-Meier curves for melanoma-specific survival (MSS) in European Organisation for Research and Treatment of Cancer cohort 18071, placebo group. (A) In all stage III patients. (B) According to American Joint Committee on Cancer version 8 (AJCCv8) classification: stage IIIA, IIIB, IIIC, and IIID. HR, hazard ratio.

FIG A1.

Kaplan-Meier curves for overall survival in the Central Malignant Melanoma Registry cohort. (A) In all stage III patients. (B) According to American Joint Committee on Cancer version 8 (AJCCv8) classification: stage IIIA, IIIB, IIIC, and IIID. HR, hazard ratio.

FIG A2.

Kaplan-Meier curves for overall survival in the European Organisation for Research and Treatment of Cancer cohort 18991, observation group. (A) In all stage III patients. (B) According to American Joint Committee on Cancer version 8 (AJCCv8) classification: stage IIIA, IIIB, IIIC, and IIID. HR, hazard ratio.

FIG A3.

Kaplan-Meier curves for overall survival in the European Organisation for Research and Treatment of Cancer cohort 18071, placebo group. (A) In all stage III patients. (B) according to American Joint Committee on Cancer version 8 (AJCCv8) classification: stage IIIA, IIIB, IIIC, and IIID. HR, hazard ratio.

FIG A4.

Reconstructed melanoma-specific survival curves for patients staged according to American Joint Committee on Cancer version 7 (AJCCv7) and American Joint Committee on Cancer version 8 (AJCCv8) for all stage III patients.

Cited by

A population-based validation study of the 8th edition UICC/AJCC TNM staging system for cutaneous melanoma.
Hynes MC, Nguyen P, Groome PA, Asai Y, Mavor ME, Baetz TD, Hanna TP. Hynes MC, et al. BMC Cancer. 2022 Jul 1;22(1):720. doi: 10.1186/s12885-022-09781-0. BMC Cancer. 2022. PMID: 35778691 Free PMC article.
Efficacy of Neoadjuvant Targeted Therapy for Borderline Resectable III B-D or IV Stage BRAF V600 Mutation-Positive Melanoma.
Czarnecka AM, Ostaszewski K, Borkowska A, Szumera-Ciećkiewicz A, Kozak K, Świtaj T, Rogala P, Kalinowska I, Koseła-Paterczyk H, Zaborowski K, Teterycz P, Tysarowski A, Makuła D, Rutkowski P. Czarnecka AM, et al. Cancers (Basel). 2021 Dec 27;14(1):110. doi: 10.3390/cancers14010110. Cancers (Basel). 2021. PMID: 35008274 Free PMC article.
Current Landscape and Open Questions on Adjuvant Therapies in Melanoma.
De Falco V, Napolitano S, Guerrera LP, Troiani T. De Falco V, et al. Dermatol Pract Concept. 2021 Jul 1;11(Suppl 1):e2021165S. doi: 10.5826/dpc.11S1a165S. eCollection 2021 Jul. Dermatol Pract Concept. 2021. PMID: 34447614 Free PMC article. Review.
The Proportion Cured of Patients with Resected Stage II-III Cutaneous Melanoma in Sweden.
Eriksson H, Utjés D, Olofsson Bagge R, Gillgren P, Isaksson K, Lapins J, Schultz IL, Lyth J, Andersson TM. Eriksson H, et al. Cancers (Basel). 2021 May 18;13(10):2456. doi: 10.3390/cancers13102456. Cancers (Basel). 2021. PMID: 34070092 Free PMC article.
Factors Influencing the Adjuvant Therapy Decision: Results of a Real-World Multicenter Data Analysis of 904 Melanoma Patients.
Lodde G, Forschner A, Hassel J, Wulfken LM, Meier F, Mohr P, Kähler K, Schilling B, Loquai C, Berking C, Hüning S, Schatton K, Gebhardt C, Eckardt J, Gutzmer R, Reinhardt L, Glutsch V, Nikfarjam U, Erdmann M, Stang A, Kowall B, Roesch A, Ugurel S, Zimmer L, Schadendorf D, Livingstone E. Lodde G, et al. Cancers (Basel). 2021 May 12;13(10):2319. doi: 10.3390/cancers13102319. Cancers (Basel). 2021. PMID: 34065995 Free PMC article.

References

1. Garbe C, Keim U, Eigentler TK, et al. Time trends in incidence and mortality of cutaneous melanoma in Germany. J Eur Acad Dermatol Venereol. 2019;33:1272–1280. - PubMed
1. Leiter U, Eigentler T, Garbe C. Epidemiology of skin cancer. Adv Exp Med Biol. 2014;810:120–140. - PubMed
1. Eggermont AMM, Robert C, Ribas A. The new era of adjuvant therapies for melanoma. Nat Rev Clin Oncol. 2018;15:535–536. - PubMed
1. Kudchadkar RR, Michielin O, van Akkooi ACJ. Practice-changing developments in stage III melanoma: Surgery, adjuvant targeted therapy, and immunotherapy. Am Soc Clin Oncol Educ Book. 2018;38:759–762. - PubMed
1. Grob JJ, Garbe C, Ascierto P, et al. Adjuvant melanoma therapy with new drugs: Should physicians continue to focus on metastatic disease or use it earlier in primary melanoma? Lancet Oncol. 2018;19:e720–e725. - PubMed

Publication types

MeSH terms

LinkOut - more resources

Full Text Sources
- Atypon
- Europe PubMed Central
- Ovid Technologies, Inc.
- PubMed Central
Medical
- MedlinePlus Health Information

What is the life expectancy with stage 3 melanoma?

Prognosis for Stage 3 Melanoma: With appropriate treatment, Stage III melanoma is considered intermediate to high risk for recurrence or metastasis. With all melanoma, the earlier it is detected and treated, the better. The 5-year survival rate as of 2018 for regional melanoma (Stage III) is 63.6%.

What are the chances of surviving stage 3 melanoma?

Five-Year Survival Rate by Melanoma Stage: Localized melanoma: Stage 0, Stage I, and Stage II: 98.4% Regional melanoma: Stage III: 63.6% Metastatic melanoma: Stage IV: 22.5%

Is Stage 3 melanoma considered advanced?

Considered an advanced form of skin cancer, a stage III melanoma may have spread beyond the original tumor to one or multiple nearby lymph nodes. This stage also includes disease that has travelled from the primary site but not yet reached local lymph nodes.

How serious is Stage 3C melanoma?

Doctors divide stage 3 melanoma into three categories: 3A, 3B, and 3C. Stage 3A is the least serious, while stage 3C is the most advanced. Staging depends on the location of the cancer, the size of the tumors, and whether they have ulcerated.